Drug Development

Pharmaceutical company submits IND for cancer drug, makes board appointment

Published in Cancer Weekly, January 18th, 2005

Tapestry Pharmaceuticals, Inc. (TPPH) has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for its novel taxane, TPI 287.

In preclinical testing TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and has shown superior inhibition of tumor burden in certain animal xenograft models when tested against standard comparative agents.

The in vitro activity was seen across multiple cell lines including those cell lines known to be sensitive to taxanes as well as cell lines known to be resistant to currently available taxanes. Taxane resistant cell lines in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-01-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry